New pill shows promise in early trial for tough blood cancers
NCT ID NCT04139434
First seen Jan 27, 2026 · Last updated May 21, 2026 · Updated 21 times
Summary
This early-phase study tested an experimental pill called LP-108, taken alone or with another drug (azacitidine), in 32 adults with blood cancers (MDS, CMML, or AML) that returned or didn't respond to prior therapy. The main goals were to find the safest dose and understand how the drug moves through the body. Researchers also looked for signs that the cancer shrank or disappeared.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital San Pedro de Alcántara
Cáceres, Cáceres, 10003, Spain
-
Institut Català d'oncologia - ICO Badalona
Badalona, Barcelona, 08916, Spain
-
Instituto de Investigación Sanitaria La Fe
Valencia, Valencia, CP 46026, Spain
-
MD Anderson Cancer Center
Huston, Texas, 77030, United States
-
Ohio State Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.